ReviewBrain informatics2026
RDoC-informed explainable AI as a paradigm for multilevel Alzheimer's disease diagnosis and progression prediction: a systematic review.
Review in Brain informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Explainable Artificial Intelligence (XAI) is gaining popularity in early diagnosis and monitoring of dementia. Herein, we recommend the incorporation of the National Institute of Mental Health's Research Domain Criteria (NIMH-RDoC) framework with XAI-informed diagnostic protocols to help establish diagnosis at early stages of Alzheimer's disease (AD). RDoC has a dimensional structure that extends across units of analysis from genes and molecules to circuits, physiology, behavior, and introspection. By restructuring diverse features as inputs including apolipoprotein E (APOE) genotype, amyloid and tau biomarkers, computational neuroimaging-informed cortical atrophy, Positron Emission Tomography (PET) hypometabolism, quantitative electroencephalography (qEEG) rhythms, cognitive tests, and digital behavioral markers), onto RDoC units provides more insightful and inclusive models. In this context, data-driven approaches such as XAI can achieve not only increased interpretability but also enhance their mechanistic validity. Such an innovative approach places data-driven model outputs within neurobiologically based domains such as Cognitive Systems, Negative Valence, and Arousal/Regulatory Systems. Our synthesis suggests that a 'converging RDoC and XAI' approach may help bolster the coherence of AD biomarkers, promote model exploration in clinical decision-making. This approach is also expected to provide a strategic roadmap for translational neuroscience and personalized medicine. Another major aim of this study is to critically analyze current XAI approaches used in dementia research, particularly the diagnostic and prognostic aspects. By explicitly grounding explanations in RDoC cognitive domains and paradigms, the framework also aims to make model outputs meaningful in terms of specific mental functions (e.g., episodic memory, cognitive control), thereby supporting neuropsychologically-informed diagnosis, categorization, and communication with patients and caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.